Precision prostate treatment that preserves what matters most to men

Incision-free, radiation-free, and versatile prostate treatment with no hospital stay

The TULSA Procedure is performed inside an MRI scanner, allowing your doctor to see the prostate and surrounding structures in real time. This helps them plan and adjust the treatment based on your unique prostate size, shape, and location of disease.

Using this guidance, directional ultrasound energy is delivered through the urethra to precisely target prostate tissue while helping protect nearby nerves and healthy structures. Real-time monitoring allows the physician to treat only what’s needed, which may help reduce the risk of serious side effects such as urinary incontinence and erectile dysfunction. The procedure is completed in a single session—with no incisions, no radiation and no hospital stay.

Personalized treatment that delivers exactly the benefits you’re looking for

Better outcomes

Compared to surgery1

Return to Normal Function

At six month follow up, men with intermediate-risk prostate cancer had better preservation of both erectile function and urinary continence together, with TULSA Procedure vs. surgery.1

Quicker recovery

Compared to surgery2

Return to Feeling Good

TULSA patients had zero blood loss, no overnight hospital stay, less pain, faster return to work, and better overall health.2

Long-lasting

Cancer control at five years after a single whole-gland ablation.3

Return to Peace of Mind

For men with localized prostate cancer, 78% of men required no further cancer treatment, providing peace of mind for patients.3

Significant improvements

In BPH symptoms4.

Return to Freedom

At 12 months, 96% of men with symptoms discontinued BPH medications after TULSA Procedure, while 94% preserved erectile function, and 100% maintained urinary control.4

In prostate therapy, success depends on three essentials: seeing the disease accurately, treating it precisely, and confirming it completely. For three of the most common prostate issues, the TULSA Procedure may help. Click on one of the options below to learn more.

Landmark CAPTAIN clinical trial

Traditionally, many men with prostate cancer have been treated with radical prostatectomy, a surgery that removes the entire prostate gland.

Results from the landmark CAPTAIN randomized control trial has shown that men treated with the TULSA Procedure experience better preservation of urinary continence and erectile function, less pain after the procedure, faster recovery, fewer hospitalizations for complications, and a quicker return to normal activities and work compared with traditional prostate surgery.1

Important Safety Information

All surgical treatments carry risks, and individual outcomes may vary based on patient and disease characteristics. The most common side effects of the TULSA Procedure are mild and temporary, such as urinary symptoms, blood in the urine, minor infections, discomfort in the pelvic, genital, abdominal or anorectal area.

More serious risks, though rare, can include anesthesia risk, sexual dysfunction, urine leakage, urethral discharge, urinary tract infection, deep vein thrombosis, rectal injury, and tightening of the bladder outlet and/or urethra, which may require additional intervention. Patients may also experience worsening urinary symptoms, such as increased frequency, urgency, or the need to urinate at night.

No claim is made that TULSA Procedure will cure any medical condition or eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required. Not all patients will experience the same results.

Rx only. TULSA-PRO is indicated for ultrasound ablation of prostate tissue.

References
  1. Klotz, et al. “Randomized control trial evaluating MRI-guided transurethral ultrasound ablation (TULSA) versus radical prostatectomy.” European Association of Urology 2026 Congress.
  2. Olivares, et al. “Perioperative outcomes from a randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robot-assisted radical prostatectomy (RARP).” The Journal of Clinical Oncology (2026).
  3. Eggener, et al. “Pivotal study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: 5-year follow up.” Urologic Oncology (2024).
  4. Viitala et al, “Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.” BJU Int (2025).